{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:54:46Z","timestamp":1790110486254,"version":"4.0.1"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Takeda Vaccines, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>Antibody affinity maturation is a critical step in development of functional antiviral immunity; however, accurate measurement of affinity maturation of polyclonal serum antibody responses to particulate antigens such as virions is challenging. We describe a novel avidity assay employing biolayer interferometry and dengue virus-like particles. After validation using anti-dengue monoclonal antibodies, the assay was used to assess avidity of antibody responses to a tetravalent dengue vaccine candidate (TAK-003) in children, adolescents, and adults during two phase 2 clinical trials conducted in dengue-endemic regions. Vaccination increased avidity index and avidity remained high through 1 year postvaccination. Neutralizing antibody titers and avidity index did not correlate overall; however, a correlation was observed between neutralizing antibody titer and avidity index in those subjects with the highest degree of antibody affinity maturation. Therefore, vaccination with TAK-003 stimulates polyclonal affinity maturation and functional antibody responses, including neutralizing antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trials Registration<\/jats:title><jats:p>NCT01511250 and NCT02302066.<\/jats:p><\/jats:sec>","DOI":"10.1093\/infdis\/jiab064","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T12:09:09Z","timestamp":1611922149000},"page":"1533-1544","source":"Crossref","is-referenced-by-count":16,"title":["Development of a Novel Assay to Assess the Avidity of Dengue Virus-Specific Antibodies Elicited in Response to a Tetravalent Dengue Vaccine"],"prefix":"10.1093","volume":"225","author":[{"given":"Isamu","family":"Tsuji","sequence":"first","affiliation":[{"name":"Discovery Research, Vaccines Business Unit, Takeda Pharmaceuticals Inc. Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dominguez","sequence":"additional","affiliation":[{"name":"Discovery Research, Vaccines Business Unit, Takeda Pharmaceuticals Inc. Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Egan","sequence":"additional","affiliation":[{"name":"Discovery Research, Vaccines Business Unit, Takeda Pharmaceuticals Inc. Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansi J","family":"Dean","sequence":"additional","affiliation":[{"name":"Discovery Research, Vaccines Business Unit, Takeda Pharmaceuticals Inc. Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"key":"2022050519472445700_CIT0001","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev-immunol-020711-075032","article-title":"Germinal centers","volume":"30","author":"Victora","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"2022050519472445700_CIT0002","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.coviro.2015.04.002","article-title":"Strategies to guide the antibody affinity maturation process","volume":"11","author":"Doria-Rose","year":"2015","journal-title":"Curr Opin Virol"},{"key":"2022050519472445700_CIT0003","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nature13764","article-title":"Rapid development of broadly influenza neutralizing antibodies through redundant mutations","volume":"516","author":"Pappas","year":"2014","journal-title":"Nature"},{"key":"2022050519472445700_CIT0004","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/s41467-019-09914-3","article-title":"Differential human antibody repertoires following Zika infection and the implications for serodiagnostics and disease outcome","volume":"10","author":"Ravichandran","year":"2019","journal-title":"Nat Commun"},{"key":"2022050519472445700_CIT0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"Walker","year":"2009","journal-title":"Science"},{"key":"2022050519472445700_CIT0006","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nature06890","article-title":"Rapid cloning of high-affinity human monoclonal antibodies against influenza virus","volume":"453","author":"Wrammert","year":"2008","journal-title":"Nature"},{"key":"2022050519472445700_CIT0007","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1586\/14760584.2016.1128831","article-title":"How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses","volume":"15","author":"Klasse","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"2022050519472445700_CIT0008","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1099\/0022-1317-83-9-2091","article-title":"Occupancy and mechanism in antibody-mediated neutralization of animal viruses","volume":"83","author":"Klasse","year":"2002","journal-title":"J Gen Virol"},{"key":"2022050519472445700_CIT0009","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0065-2776(01)77018-6","article-title":"The antiviral activity of antibodies in vitro and in vivo","volume":"77","author":"Parren","year":"2001","journal-title":"Adv Immunol"},{"key":"2022050519472445700_CIT0010","doi-asserted-by":"crossref","first-page":"e2274","DOI":"10.1371\/journal.pntd.0002274","article-title":"Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans","volume":"7","author":"Puschnik","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2022050519472445700_CIT0011","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41590-018-0210-3","article-title":"The immune response against flaviviruses","volume":"19","author":"Slon Campos","year":"2018","journal-title":"Nat Immunol"},{"key":"2022050519472445700_CIT0012","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1080\/19420862.2016.1267086","article-title":"An elaborate landscape of the human antibody repertoire against enterovirus 71 infection is revealed by phage display screening and deep sequencing","volume":"9","author":"Chen","year":"2017","journal-title":"MAbs"},{"key":"2022050519472445700_CIT0013","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.4049\/jimmunol.1303334","article-title":"Single-cell and deep sequencing of IgG-switched macaque B cells reveal a diverse Ig repertoire following immunization","volume":"192","author":"Sundling","year":"2014","journal-title":"J Immunol"},{"key":"2022050519472445700_CIT0014","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1016\/j.vaccine.2014.04.005","article-title":"Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule","volume":"32","author":"Boxus","year":"2014","journal-title":"Vaccine"},{"key":"2022050519472445700_CIT0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jim.2012.02.017","article-title":"Practical quantitative and kinetic applications of bio-layer interferometry for toxicokinetic analysis of a monoclonal antibody therapeutic","volume":"379","author":"Dysinger","year":"2012","journal-title":"J Immunol Methods"},{"key":"2022050519472445700_CIT0016","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1006\/abio.1993.1355","article-title":"Determination of rate and equilibrium binding constants for macromolecular interactions using surface plasmon resonance: use of nonlinear least squares analysis methods","volume":"212","author":"O\u2019Shannessy","year":"1993","journal-title":"Anal Biochem"},{"key":"2022050519472445700_CIT0017","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1080\/21645515.2016.1168954","article-title":"Evaluation of potential immunogenicity differences between Pandemrix\u2122 and Arepanrix\u2122","volume":"12","author":"Canelle","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2022050519472445700_CIT0018","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.4049\/jimmunol.1800323","article-title":"Qualified biolayer interferometry avidity measurements distinguish the heterogeneity of antibody interactions with Plasmodium falciparum circumsporozoite protein antigens","volume":"201","author":"Dennison","year":"2018","journal-title":"J Immunol"},{"key":"2022050519472445700_CIT0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2013.11.026","article-title":"Surface plasmon resonance measurements of plasma antibody avidity during primary and secondary responses to anthrax protective antigen","volume":"404","author":"Lynch","year":"2014","journal-title":"J Immunol Methods"},{"key":"2022050519472445700_CIT0020","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3389\/fimmu.2016.00640","article-title":"Nasal immunization confers high avidity neutralizing antibody response and immunity to primary and recurrent genital herpes in guinea pigs","volume":"7","author":"Persson","year":"2016","journal-title":"Front Immunol"},{"key":"2022050519472445700_CIT0021","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12985-018-0970-2","article-title":"Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope","volume":"15","author":"Metz","year":"2018","journal-title":"Virol J"},{"key":"2022050519472445700_CIT0022","doi-asserted-by":"crossref","first-page":"139ra183","DOI":"10.1126\/scitranslmed.3003888","article-title":"The structural basis for serotype-specific neutralization of dengue virus by a human antibody","volume":"4","author":"Teoh","year":"2012","journal-title":"Sci Transl Med"},{"key":"2022050519472445700_CIT0023","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"2022050519472445700_CIT0024","volume-title":"Dengue: guidelines for diagnosis, treatment, prevention and control: new edition","author":"World Health Organization","year":"2009"},{"key":"2022050519472445700_CIT0025","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.4049\/jimmunol.132.3.1529","article-title":"Heterogeneity of infection enhancement of dengue 2 strains by monoclonal antibodies","volume":"132","author":"Halstead","year":"1984","journal-title":"J Immunol"},{"key":"2022050519472445700_CIT0026","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nm1240","article-title":"Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus","volume":"11","author":"Oliphant","year":"2005","journal-title":"Nat Med"},{"key":"2022050519472445700_CIT0027","doi-asserted-by":"crossref","first-page":"e00873","DOI":"10.1128\/mBio.00873-13","article-title":"The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein","volume":"4","author":"Smith","year":"2013","journal-title":"mBio"},{"key":"2022050519472445700_CIT0028","doi-asserted-by":"crossref","first-page":"e1000823","DOI":"10.1371\/journal.ppat.1000823","article-title":"The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1","volume":"6","author":"Shrestha","year":"2010","journal-title":"PLoS Pathog"},{"key":"2022050519472445700_CIT0029","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1073\/pnas.1200566109","article-title":"Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions","volume":"109","author":"de Alwis","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022050519472445700_CIT0030","doi-asserted-by":"crossref","first-page":"e6341","DOI":"10.1038\/ncomms7341","article-title":"Highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins","volume":"6","author":"Fibriansah","year":"2015","journal-title":"Nat Commun"},{"key":"2022050519472445700_CIT0031","doi-asserted-by":"crossref","first-page":"8826","DOI":"10.1128\/JVI.01314-13","article-title":"Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection","volume":"87","author":"Sukupolvi-Petty","year":"2013","journal-title":"J Virol"},{"key":"2022050519472445700_CIT0032","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/infdis\/jiv762","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine candidate in healthy children and adults in dengue-endemic regions: a randomized, placebo-controlled phase 2 study","volume":"213","author":"Sirivichayakul","year":"2016","journal-title":"J Infect Dis"},{"key":"2022050519472445700_CIT0033","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1473-3099(17)30166-4","article-title":"Safety and immunogenicity of one versus two doses of Takeda\u2019s tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study","volume":"17","author":"S\u00e1ez-Llorens","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2022050519472445700_CIT0034","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study","volume":"14","author":"Osorio","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2022050519472445700_CIT0035","volume-title":"ASTM E685-93(2013). Standard practice for testing fixed-wavelength photometric detectors used in liquid chromatography","author":"ASTM International","year":"2013"},{"key":"2022050519472445700_CIT0036","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.antiviral.2016.01.002","article-title":"The development of therapeutic antibodies against dengue virus","volume":"128","author":"Fibriansah","year":"2016","journal-title":"Antiviral Res"},{"key":"2022050519472445700_CIT0037","first-page":"47","article-title":"Antibodies","volume-title":"Affinity chromatography","author":"GE Healthcare","year":"2016"},{"key":"2022050519472445700_CIT0038","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/intimm\/dxz049","article-title":"Requirement for memory B-cell activation in protection from heterologous influenza virus reinfection","volume":"31","author":"Leach","year":"2019","journal-title":"Int Immunol"},{"key":"2022050519472445700_CIT0039","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jcv.2015.06.003","article-title":"Antibody avidity following secondary dengue virus type 2 infection across a range of disease severity","volume":"69","author":"Lau","year":"2015","journal-title":"J Clin Virol"},{"key":"2022050519472445700_CIT0040","doi-asserted-by":"crossref","first-page":"12562","DOI":"10.1128\/JVI.00871-13","article-title":"High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection","volume":"87","author":"Tsai","year":"2013","journal-title":"J Virol"},{"key":"2022050519472445700_CIT0041","doi-asserted-by":"crossref","first-page":"336ra362","DOI":"10.1126\/scitranslmed.aaf0618","article-title":"Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages","volume":"8","author":"Zhang","year":"2016","journal-title":"Sci Transl Med"},{"key":"2022050519472445700_CIT0042","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1038\/s41467-019-11296-5","article-title":"Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans","volume":"10","author":"Khurana","year":"2019","journal-title":"Nat Commun"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab064\/36588240\/jiab064.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/9\/1533\/43546376\/jiab064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/9\/1533\/43546376\/jiab064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T16:29:13Z","timestamp":1697732953000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/225\/9\/1533\/6127289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,2,3]]},"published-print":{"date-parts":[[2022,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab064","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2021,2,3]]}}}